Covidien’s Mallinckrodt to acquire CNS Therapeutics

THE PHARMACEUTICAL ARM of med-tech Covidien LLC has entered into a definitive agreement to acquire CNS Therapeutics Inc. for $100 million.  / COURTESY COVIDIEN LTD.
THE PHARMACEUTICAL ARM of med-tech Covidien LLC has entered into a definitive agreement to acquire CNS Therapeutics Inc. for $100 million. / COURTESY COVIDIEN LTD.
MANSFIELD – Medical device maker Covidien LLC’s pharmaceutical arm, Mallinckrodt, has entered into a definitive agreement to acquire St. Paul, Minn.-based CNS Therapeutics Inc. CNS, a privately help specialty pharmaceutical company, focuses on developing and commercializing products for site-specific administration to the central nervous system for the treatment of neurological disorders and chronic pain. Mallinckrodt…
To read the full story, Subscribe or
Subscribe to PBN
- Advertisement -